share_log
Reuters ·  May 8 07:03
Verve Therapeutics Inc - Received First Milestone Payment From Eli Lilly for Collaboration on in Vivo Gene Editing Program Targeting Lipoprotein(a)
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment